

**AMENDMENT**

**In the Claims:**

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1. (Previously presented) A method of delivering a selected gene to a muscle cell or tissue, said method comprising:
  - (a) providing a recombinant adeno-associated virus (AAV) virion which comprises an AAV vector, said AAV vector comprising said selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of said selected gene; and
  - (b) introducing said recombinant AAV virion into said muscle cell or tissue, wherein said muscle cell or tissue is selected from the group consisting of smooth muscle, cardiac muscle and a cardiomyocyte.
2. (Cancelled)
3. (Original) The method of claim 1, wherein said muscle cell or tissue is derived from smooth muscle.
4. (Original) The method of claim 1, wherein said muscle cell or tissue is derived from cardiac muscle.
5. (Cancelled)
6. (Cancelled)
7. (Original) The method of claim 1, wherein said muscle cell is a cardiomyocyte.

8. (Original) The method of claim 1, wherein said recombinant AAV virion is introduced into said muscle cell *in vivo*.

9. (Original) The method of claim 1, wherein said recombinant AAV virion is introduced into said muscle cell *in vitro*.

10. (Original) The method of claim 1, wherein said selected gene encodes a therapeutic protein.

11. (Original) The method of claim 10, wherein said protein is erythropoietin.

12. (Previously presented) A cardiomyocyte transduced with a recombinant AAV virion which comprises an AAV vector, said AAV vector comprising a selected gene operably linked to control elements capable of directing the *in vivo* transcription and translation of said selected gene.

13.-15. (Cancelled)

16. (Previously presented) The cardiomyocyte of claim 12, wherein said selected gene encodes erythropoietin.

17. (Cancelled)

18. (Original) A method of treating an acquired or inherited disease in a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector, said AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of said selected gene when present in said subject; and

(b) administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

19. (Cancelled)

20. (Original) A method for delivering a therapeutically effective amount of a protein systemically to a mammalian subject comprising:

(a) introducing a recombinant AAV virion into a muscle cell or tissue *in vitro* to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector, said AAV vector comprising a selected gene operably linked to control elements capable of directing the transcription and translation of said selected gene when present in said subject; and

(b) administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).

21. (Cancelled)

22. (Cancelled)